Three deaths in CAR-T trials prompt halt by Novartis; Bristol Myers programs also paused

Novartis, Bristol Myers pause autoimmune CAR-T trials due to safety concerns

The deaths of three study participants led Novartis to halt development of rap-cel in multiple indications, while “transient” side effects pushed Bristol Myers to voluntarily pause its zola-cel program.